Skip to main content
Top
Published in: Supportive Care in Cancer 9/2022

21-03-2022 | Metastasis | Commentary

One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost–benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ)

Authors: Vittorio Fusco, Giuseppina Campisi, Alberto Bedogni

Published in: Supportive Care in Cancer | Issue 9/2022

Login to get access

Abstract

Antiresorptive drugs (bisphosphonates and denosumab) have become the cornerstone of medical supportive treatment of bone metastases in solid cancer patients. In the beginning, the choice of available antiresorptive agents was limited to bisphosphonates and the treatment options restricted principally to monthly pamidronate and monthly zoledronic acid. Introduction of new antiresorptive therapies (monthly denosumab) and schedules (zoledronic acid every 3 months, upfront or after initial period of monthly infusion) in the last decade increased the range of available options, thus challenging treatment decision making. Direct and indirect costs of very different treatment options are difficult to interpret in a global cost–benefit analysis. In addition, awareness of the increased risk of medication-related osteonecrosis of the jaw (MRONJ) in bone metastatic cancer patients receiving long-term antiresorptive medications is likely to influence therapy choice in the real-life scenario. We discuss the possible threat of MRONJ risk underestimation and the need for long-term risk stratification of patients based on actuarial data, the role of bisphosphonates and denosumab in that scenario, and the emerging role of surgical therapy to successfully cure MRONJ, in the light of the improved quality of life and survival of patients with bone metastases from solid cancers.
Literature
1.
go back to reference Srivastava A, Nogueras Gonzalez GM, Geng Y, Won AM, Cabanillas ME, Naing A, Myers JN, Li Y, Chambers MS (2021) Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis. Support Care Cancer 29(5):2305–2317. https://doi.org/10.1007/s00520-020-05882-3CrossRefPubMed Srivastava A, Nogueras Gonzalez GM, Geng Y, Won AM, Cabanillas ME, Naing A, Myers JN, Li Y, Chambers MS (2021) Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis. Support Care Cancer 29(5):2305–2317. https://​doi.​org/​10.​1007/​s00520-020-05882-3CrossRefPubMed
3.
go back to reference Ikesue H, Mouri M, Tomita H, Hirabatake M, Ikemura M, Muroi N, Yamamoto S, Takenobu T, Tomii K, Kawakita M, Katoh H, Ishikawa T, Yasui H, Hashida T (2021) Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases. Support Care Cancer 29(8):4763–4772. https://doi.org/10.1007/s00520-021-06018-xCrossRefPubMedPubMedCentral Ikesue H, Mouri M, Tomita H, Hirabatake M, Ikemura M, Muroi N, Yamamoto S, Takenobu T, Tomii K, Kawakita M, Katoh H, Ishikawa T, Yasui H, Hashida T (2021) Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases. Support Care Cancer 29(8):4763–4772. https://​doi.​org/​10.​1007/​s00520-021-06018-xCrossRefPubMedPubMedCentral
4.
go back to reference Rossi M, Gambino A, Cabras M, Alessio M, Fusco V (2021) Persistence, compliance, discontinuation rates and switch rates in denosumab and bisphosphonate treatment of bone metastases in cancer patients: reasons of switch, osteonecrosis of the jaw (ONJ) and other critical points. Support Care Cancer 29(8):4185–4186. https://doi.org/10.1007/s00520-021-06100-4CrossRefPubMed Rossi M, Gambino A, Cabras M, Alessio M, Fusco V (2021) Persistence, compliance, discontinuation rates and switch rates in denosumab and bisphosphonate treatment of bone metastases in cancer patients: reasons of switch, osteonecrosis of the jaw (ONJ) and other critical points. Support Care Cancer 29(8):4185–4186. https://​doi.​org/​10.​1007/​s00520-021-06100-4CrossRefPubMed
7.
go back to reference Ikesue H, Doi K, Morimoto M, Hirabatake M, Muroi N, Yamamoto S, Takenobu T, Hashida T (2021) Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis. Support Care Cancer 4:524. https://doi.org/10.1007/s00520-021-06634-7 (Online ahead of print)CrossRef Ikesue H, Doi K, Morimoto M, Hirabatake M, Muroi N, Yamamoto S, Takenobu T, Hashida T (2021) Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis. Support Care Cancer 4:524. https://​doi.​org/​10.​1007/​s00520-021-06634-7 (Online ahead of print)CrossRef
12.
go back to reference Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, Migliorati CA, Khan A, Morrison A, Anderson H, Murphy BA, Alston-Johnson D, Mendes RA, Beadle BM, Jensen SB, Saunders DP (2019) Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. J Clin Oncol 37(25):2270–2290. https://doi.org/10.1200/JCO.19.01186CrossRefPubMed Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, Migliorati CA, Khan A, Morrison A, Anderson H, Murphy BA, Alston-Johnson D, Mendes RA, Beadle BM, Jensen SB, Saunders DP (2019) Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. J Clin Oncol 37(25):2270–2290. https://​doi.​org/​10.​1200/​JCO.​19.​01186CrossRefPubMed
14.
go back to reference Fusco V, Santini D, Campisi G, Bertoldo F, Lanzetta G, Ibrahim T, Bertetto O, Numico G, Addeo A, Berruti A, Bettini G, Saia G, Bedogni A (2020) Comment on Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO Clinical Practice Guideline Summary. JCO Oncol Pract 16(3):142–145. https://doi.org/10.1200/JOP.19.00645CrossRefPubMed Fusco V, Santini D, Campisi G, Bertoldo F, Lanzetta G, Ibrahim T, Bertetto O, Numico G, Addeo A, Berruti A, Bettini G, Saia G, Bedogni A (2020) Comment on Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO Clinical Practice Guideline Summary. JCO Oncol Pract 16(3):142–145. https://​doi.​org/​10.​1200/​JOP.​19.​00645CrossRefPubMed
15.
go back to reference Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, Dhesy-Thind SK, Dillmon MS, Eisen A, Frank ES, Jagsi R, Jimenez R, Theriault RL, Vandenberg TA, Yee GC, Moy B (2017) Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update. J Clin Oncol 35(35):3978–3986. https://doi.org/10.1200/JCO.2017.75.4614CrossRefPubMed Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, Dhesy-Thind SK, Dillmon MS, Eisen A, Frank ES, Jagsi R, Jimenez R, Theriault RL, Vandenberg TA, Yee GC, Moy B (2017) Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update. J Clin Oncol 35(35):3978–3986. https://​doi.​org/​10.​1200/​JCO.​2017.​75.​4614CrossRefPubMed
18.
go back to reference Loyson T, Van Cann T, Schöffski P, Clement PM, Bechter O, Spriet I, Coropciuc R, Politis C, Vandeweyer RO, Schoenaers J, Dumez H, Berteloot P, Neven P, Nackaerts K, Woei-A-Jin FJSH, Punie K, Wildiers H, Beuselinck B (2018) Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab. Acta Clin Belg 73(2):100–109. https://doi.org/10.1080/17843286.2017.1348001CrossRefPubMed Loyson T, Van Cann T, Schöffski P, Clement PM, Bechter O, Spriet I, Coropciuc R, Politis C, Vandeweyer RO, Schoenaers J, Dumez H, Berteloot P, Neven P, Nackaerts K, Woei-A-Jin FJSH, Punie K, Wildiers H, Beuselinck B (2018) Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab. Acta Clin Belg 73(2):100–109. https://​doi.​org/​10.​1080/​17843286.​2017.​1348001CrossRefPubMed
20.
go back to reference van Cann T, Loyson T, Verbiest A, Clement PM, Bechter O, Willems L, Spriet I, Coropciuc R, Politis C, Vandeweyer RO, Schoenaers J, Debruyne PR, Dumez H, Berteloot P, Neven P, Nackaerts K, Woei-A-Jin FJSH, Punie K, Wildiers H, Beuselinck B (2018) Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors. Support Care Cancer 26(3):869–878. https://doi.org/10.1007/s00520-017-3903-5CrossRefPubMed van Cann T, Loyson T, Verbiest A, Clement PM, Bechter O, Willems L, Spriet I, Coropciuc R, Politis C, Vandeweyer RO, Schoenaers J, Debruyne PR, Dumez H, Berteloot P, Neven P, Nackaerts K, Woei-A-Jin FJSH, Punie K, Wildiers H, Beuselinck B (2018) Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors. Support Care Cancer 26(3):869–878. https://​doi.​org/​10.​1007/​s00520-017-3903-5CrossRefPubMed
21.
go back to reference Cabras M, Gambino A, Conrotto D,Garrone M, Fasciolo A, Basano L, Gilardetti M, Galassi C, Fusco V. (2021) Survival of metastatic cancer patients and myeloma patients after diagnosis of Osteonecrosis of Jaws (ONJ). Potential impact on ONJ treatment strategies. https://www.qeios.com/read/IKLIWH Cabras M, Gambino A, Conrotto D,Garrone M, Fasciolo A, Basano L, Gilardetti M, Galassi C, Fusco V. (2021) Survival of metastatic cancer patients and myeloma patients after diagnosis of Osteonecrosis of Jaws (ONJ). Potential impact on ONJ treatment strategies. https://​www.​qeios.​com/​read/​IKLIWH
Metadata
Title
One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost–benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ)
Authors
Vittorio Fusco
Giuseppina Campisi
Alberto Bedogni
Publication date
21-03-2022
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 9/2022
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-022-06982-y

Other articles of this Issue 9/2022

Supportive Care in Cancer 9/2022 Go to the issue
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare